Cytosponge as a risk stratification tool in patients overdue barrett’s surveillance due to Covid-19
Gut
; 70(Suppl 4):A34, 2021.
Article
in English
| ProQuest Central | ID: covidwho-1504739
ABSTRACT
HFR-1 Table 1Demographics, baseline Barrett’s baseline information and outcome of all patients who have completed the Cytosponge ® procedure. * 2 patients still awaiting endoscopic assessment. NDBE Non-Dysplastic Barrett’s Oesophagus, INDEF Indefinite for dysplasia, LGD Low-Grade Dysplasia, IMC intramucosal adenocarcinoma TFF3 - Atypia - P53 - TFF3 + Atypia - P53 - TFF3 -/+ Atypia + P53 - TFF3 + Atypia + P53 + Number of patients 14 26 12 4 MF 12 2 20 6 11 1 4 0 Median maximal BE length (cm) 2.5 5 5 6 Triage decision Repeat Cytosponge®/endoscopy within 24 months Endoscopy in 12 months Endoscopy within 3 months Endoscopy within 3 months Endoscopy and histology findings - - NDBE 5 ATYPIA 1 INDEF 2 LGD 2 NDBE 1 LGD 2 IMC 1 ConclusionsThe Cytosponge® has proved to be an acceptable non-endoscopic tool for patients with BE under surveillance where endoscopy is not possible. Preliminary data are promising to detect dysplasia and triage patients to endoscopy early. Further large scale, longitudinal follow-up is needed.
Full text:
Available
Collection:
Databases of international organizations
Database:
ProQuest Central
Type of study:
Prognostic study
Language:
English
Journal:
Gut
Year:
2021
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS